Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 29;9:1327. doi: 10.3389/fonc.2019.01327

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Lim, Sa, Lee, Kim, Kim, Park, Ku, Park, Park, Lim, Kang, Nam and Lee.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Systematic evaluation of two-drug combination therapy in gastric PDCs (A) Representative overview of systematic evaluation of two-drug combination therapy for lapatinib with olaparib, AZD1775, AZD6738, palbociclib, savolitinib, or staurosporin. (B) Dose-response matrix for two-drug combination (left panel) and 2D (middle panel) and 3D (right panel) synergy maps. (C) Representative violin plots for synergism scores for respective drug combinations. Horizontal lines within the violin plots represent 0.25, 0.50, and 0.75 quantiles. P value was calculated by analysis of variance test. (D) Genomic landscape of gastric PDCs and gastric cancer cell lines. (E) Waterfall plot representation of two-drug combination synergism scores for each drug combination. Genomic mutation, amplification, and deletion are labeled in green, red, and blue colors, respectively.